Enhancing Effects of Oltipraz on the Development of Spontaneous Hepatic Lesions in LEC Rats

Toxicologic Pathology

Volumn 30, Issue 2, 2002, Pages 173-177

  Nakamura, Hideaki ^a   Okazaki, Kazushi ^a   Nishikawa, Akiyoshi ^a   Furukawa, Fumio ^a   Kasahara, Ken Ichiro ^a   Miyauchi, Makoto ^a   Imazawa, Takayoshi ^a   Uchida, Koji ^a   Hirose, Masao ^b  

^a NAGOYA UNIVERSITY   (Japan)

^b NATIONAL INSTITUTE OF HEALTH SCIENCES   (Japan)

Author keywords

hepatitis; LEC rat; Oltipraz

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTISCHISTOSOMAL AGENT; ASPARTATE AMINOTRANSFERASE; COPPER; GAMMA GLUTAMYLTRANSFERASE; GLUTATHIONE; LACTATE DEHYDROGENASE; OLTIPRAZ;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CELL DEATH; CONTROLLED STUDY; DISEASE EXACERBATION; JAUNDICE; KIDNEY HYPERTROPHY; KIDNEY TUBULE CELL; KUPFFER CELL; LIVER CELL; LIVER INJURY; LIVER LEVEL; LIVER TOXICITY; LIVER WEIGHT; MALE; MORTALITY; NONHUMAN; PRIORITY JOURNAL; RAT; WEIGHT GAIN;

ANIMALS; ANTICARCINOGENIC AGENTS; BODY WEIGHT; GLUTATHIONE; LIVER; MALE; ORGAN SIZE; PYRAZINES; RATS;

ANIMALIA; RODENTIA;

EID: 0036216135     PISSN: 01926233     EISSN: None     Source Type: Journal    
DOI: 10.1080/019262302753559506     Document Type: Article

References (30)

1. Ansher S., Dolan P., Bueding E. (1986). Biochemical effects of dithiolthiones. Food Chem Toxicol 24: 405-415.
2. Ansher SS, Dolan P., Bueding E. (1983). Chemoprotective effects of two dithiolthiones and of butylhydroxyanisol e against carbon tetrachloride and acetaminophen toxicity. Hepatology 3: 932-935.
3. Archer S. (1985). The chemotherapy of schistosomiasis. Ann Rev Pharmacol 25: 485-508.
4. Bueding E., Dolan P., Leroy J-P. (1982). The antischistosomal activity of oltipraz. Res Commun Chem Pathol Pharmacol 37: 293-303.
5. Buetter TM, Gallagher EP, Wang C., Stahl DL, Hayes JD, Eaton DL (1995). Induction of phase I and phase II drug-metabolizing enzyme mRNA, protein, and activity by BHA, ethoxyquin, and oltipraz. Toxicol Appl Pharmacol 135: 45-57.
6. Clapper ML, Wood M., Leahy K., Lang D., Miknyoczki S., Ruggery A. (1995). Chemopreventive activity of oltipraz against N-nitrosobis(2-oxopropyl)amine (BOP)-induced ductal pancreatic carcinoma development and effects on survival of Syrian golden hamsters. Carcinogenesis 16: 2159-2165.
7. Hissin PJ, Hilf R. (1976). A fluorometric method for determination of oxidized and reduced glutathione in tissues. Anal Biochem 27: 214-226.
8. Jacobson LP, Zhang B-C., Zhu Y-R., Wang J-B., Wu Y., Zhang Q-N., Yu L-Y., Qian G-S., Kuang S-Y., Li Y-F., Fang X., Zarba A., Chen B., Enger C., Davidson NE, Gorman MB, Gordon GB, Prochaska HJ, Egner PA, Groopman JD, Munoz A., Helzlsouer KJ, Kensler TW (1997). Oltipraz chemoprevention trial in Qidong, People's Republic of China: Study design and clinical outcomes. Cancer Epidemiol Biomarkers Prev 6: 257-265.
9. Jocelyne A-F., Karine M., Martine C., Marie-Pierre D., Fabrice M., Andre G., Pierre C., Josiane C. (1997). Oltipraz stimulates the transcription of the manganese superoxide dismutase in rat hepatocytes. Carcinogenesis 18: 2113-2117.
10. Kensler TW, Egner PA, Trush MA, Bueding E., Groopman JD (1985). Modification of aflatoxin B1 binding to DNA in vivo in rats fed phenolic antioxidants, ethoxiquin and a dithiolthione. Carcinogenesis 6: 759-763.
11. Kensler TW, Groopman JD, Sutter TR, Curphey TJ, Roebuck BD (1999). Development of cancer chemopreventive agents: Oltipraz as a paradigm. Chem Res Toxicol 12: 113-126.
12. Kensler TW, He X., Otieno M., Egner PA, Jacobson LP, Chen B., Wang J-S., Zhu Y-R., Zhang B-C., Wang J-B., Wu Y., Zhang Q-N., Qian G-S., Kuang S-Y., Fang X., Li Y-F., Yu L-Y., Prochaska HJ, Davidson NE, Gordon GB, Gorman MB, Zarba A., Enger C., Munoz A., Helzlsover KJ, Groopman JD (1998). Oltipraz chemoprevention trial in Qidong, People's Republic of China: Modulation of serum aflatoxin albumin adduct biomarkers. Cancer Epidemiol Biomarkers Prev 7: 127-134.
13. Kensler TW, Helzlsouer KJ (1995). Oltipraz: Clinical opportunities for cancer chemoprevention. J Cell Biochem (Suppl) 22: 101-107.
14. Koizumi M., Fujii J., Suzuki K., Inoue T., Inoue T., Gutteridge JMC, Taniguchi N. (1998). A marked increase in free copper levels in the plasma and liver of LEC rats: An animal model for Wilson disease and liver cancer. Free Rad Res 28: 441-450.
15. Krezel A., Bal W. (1999). Coordination chemistry of glutathione. Acta Biochim Pol 46: 567-580.
16. Li Y., Togashi Y., Sato S., Emoto T., Kang J-H., Takeichi N., Kobayashi H., Kojima Y., Une Y., Uchino J. (1991a). Abnormal copper accumulation in non-cancerous and cancerous liver tissues of LEC rats developing hereditary hepatic damage and spontaneous hepatoma. Jpn J Cancer Res 82: 490-492.
17. Li Y., Togashi Y., Sato S., Emoto T., Kang J-H., Takeichi N., Kobayashi H., Kojima Y., Une Y., Uchino J. (1991b). Spontaneous hepatic copper accumulation in Long-Evans Cinnamon rats with hereditary hepatitis. A model of Wilson's disease. J Clin Inv 87, 1858-1861.
18. Li Y., Trush MA (1994). Reactive oxygen-dependen t DNA damage resulting from the oxidation of phenolic compounds by a copper-redox cycle mechanism. Cancer Res (Suppl) 54: 1895s—1898s.
19. Meyer DJ, Harris JM, Gilmore KS, Coles B., Kensler TW, Ketterer B. (1993). Quantitation of tissue- and sex-specific induction of rat GSH transferase subunits by dietary 1,2-dithiole-3-thiones. Carcinogenesis 14: 567-572.
20. Muramatsu Y., Yamada T., Moralejo DH, Suzuki Y., Matsumoto K. (1994). Wilson's disease gene is homologous to hts causing abnormal copper transport in Long-Evans Cinnamon rats. Gastroenterology 107: 1189-1192.
21. Nishikawa A., Tanakamaru Z., Furukawa F., Lee IS, Kasahara K., Ikezaki S., Takahashi M. (1998). Chemopreventive activity of oltipraz against induction of glandular stomach carcinogenesi s in rats by N-methyl-N’-nitro-N-nitrosoguanidine. Carcinogenesis 19: 365-368.
22. Oikawa S., Yamada K., Yamashita N., Tada-Oikawa S., Kawanishi S. (1999). N-Acetylcysteine, a cancer chemopreventive agent, causes oxidative damage to cellular and isolated DNA. Carcinogenesis 20: 1485-1490.
23. Rao CV, Rivenson A., Zang E., Steele V., Kelloff G., Reddy BS (1996). Inhibition of 2-amino-1-methyl-6-phenylimidaz o[4,5]pyridine-induced lymphoma formation by oltipraz. Cancer Res 56: 3395-3398.
24. Rao CV, Tokomo K., Kelloff G., Reddy BS (1991). Inhibition by dietary oltipraz of experimental intestinal carcinogenesi s induced by azoxymethan e in male F344 rats. Carcinogenesis 12: 1051-1055.
25. Salid Ahmad M., Fazal F., Rahman A., Hadi SM, Parish JH (1992). Activities of flavonoids for the cleavage of DNA in the presence of Cu(II): Correlation with generation of active oxygen species. Carcinogenesis 13: 605-608.
26. Sasaki M., Yoshida MC, Kagami K., Takeichi N., Kobayashi H., Dempo K., Mori M. (1985). Spontaneous hepatitis in an inbred strain of Long Evans rats. Rat News Lett 14, 4-6.
27. Suemizu H., Yoshimura S., Takeichi N., Moriuchi T. (1994). Decreased expression of liver glutathione peroxidase in Long-Evans cinnamon mutant rats predisposed to hepatic damage and hepatoma. Hepatology 19: 694-700.
28. Wang JS, Shen X., Zhu YR, Zhang BC, Wang JB, Qian GS, Kuang SY, Zarba A., Egner PA, Jacobson LP, Munoz A., Helzlsouer KJ, Groopman JD, Kensler TW (1999). Protective alterations in phase 1 and 2 metabolism of aflatoxin B1 by oltipraz in residents of Qidong, People's Republic of China. J Natl Cancer Inst 91: 347-354.
29. Wu J., Forbes JR, Chen HS, Cox DW (1994). The LEC rat has a deletion in the copper transporting ATPase gene homologous to the Wilson disease gene. Nat Genet 7: 541-545.
30. Yoshida MC, Masuda R., Sasaki M., Takeichi N., Dempo K., Mori M. (1987). New mutation causing hereditary hepatitis in the laboratory rat. J Hered 78: 361-365.